FMP

FMP

Enter

ENTA - Enanta Pharmace...

photo-url-https://images.financialmodelingprep.com/symbol/ENTA.png

Enanta Pharmaceuticals, Inc.

ENTA

NASDAQ

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

6.1 USD

-0.55 (-9.02%)

Historical Prices

From:

To:

6.076.16.26.36.46.56.66.76.7309:30 AM09:49 AM10:09 AM10:28 AM10:48 AM11:08 AM11:28 AM11:47 AM12:06 PM12:26 PM12:46 PM01:05 PM01:24 PM01:43 PM02:02 PM02:25 PM02:45 PM03:04 PM03:23 PM03:42 PM

About

ceo

Dr. Jay R. Luly Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

CIK

0001177648

ISIN

US29251M1062

CUSIP

29251M106

Address

500 Arsenal Street

Phone

617 607 0800

Country

US

Employee

131

IPO Date

Mar 21, 2013

Financial Statement

-40M-30M-20M-10M010M20M2024 Q12024 Q22024 Q32024 Q42025 Q1RevenueNet Income

Earnings

-2.5-2-1.5-1-0.502023 Q12023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q4EPS Consensus

ENTA Financial Summary

CIK

0001177648

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

29251M106

ISIN

US29251M1062

Country

US

Price

6.1

Beta

0.48

Volume Avg.

540.96k

Market Cap

130.13M

Shares

-

52-Week

4.71-17.8

DCF

-7.91

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.23

P/B

-

Website

https://www.enanta.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest ENTA News

zacks.com

Feb 14, 2025

Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind...

Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com

Feb 10, 2025

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue ...

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.58 per share a year ago.

businesswire.com

Feb 10, 2025

Enanta Pharmaceuticals Reports Financial Results for its Fis...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended December 31, 2024. “2025 is primed to be a pivotal year for Enanta as we execute on multiple catalysts across our pipeline, including progression of our RSV compounds and expansion of our immunology portfolio. Recruitment for RSV.

businesswire.com

Dec 24, 2024

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Pate...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (“the '953 Patent”) i.

zacks.com

Dec 23, 2024

Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This S...

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

businesswire.com

Dec 9, 2024

Enanta Pharmaceuticals Announces Positive Topline Results fr...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from the first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV). An antiviral effect was observed for the primary and secondary virology endpoi.

businesswire.com

Dec 6, 2024

Enanta Pharmaceuticals to Present Topline Results from First...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory sync.

zacks.com

Nov 25, 2024

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenu...

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.33 per share a year ago.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep